Comparison of itraconazole (R51,211) and ketoconazole in the treatment of experimental candidal vaginitis in rats on schedules of 3 and 5 days revealed significantly superior results with itraconazole at all dosages (1.0 to 7.5 mg/kg) studied, but was particularly evident at 1.0 and 2.5 mg/kg. A single 25-mg/kg dose of itraconazole was as effective as 5 daily 5-mg/kg doses of itraconazole.
The imidazole derivatives miconazole, clotrimazole, and econazole administered topically and oral ketoconazole are highly effective in the treatment of vulvovaginal candidiasis (1, 2) . Itraconazole (R51,211) is a new oral imidazole ( Fig. 1 ) which, like ketoconazole, is thought to inhibit cell membrane ergosterol synthesis. Preliminary in vitro data suggest that this agent has considerably more activity against Candida albicans in addition to a broader spectrum of activity, which includes Aspergillus sp. (J. Van MICs of ketoconazole and itraconazole against 58 clinical vaginal isolates of C. albicans obtained from women with candida vaginitis were measured by agar dilution with an inoculum of 5 x 104 organisms as previously described (3). All isolates were maintained on agar slants at 4°C. The 50% MICs for itraconazole and ketoconazole were 0.16 and 0.2 pg/ml, respectively, and the 90% MICs for itraconazole and ketoconazole were 2.0 and 4.8 ,ug/ml, respectively.
Pseudoestrous was induced in 170 oophorectomized female Sprague-Dawley rats (175 to 200 g) by subcutaneous injection of estradiol valerate in sesame oil (0.5 mg/0.1 ml) (E. R. Squibb & Sons, Princeton, N.J.) and was maintained by similar weekly injections. At 48 h after the initial estrogen injection, rats were inoculated vaginally with 104 C. albicans GMO2 blastospores (MICs of ketoconazole and itraconazole were each 0.2 ,ug/ml) suspended in 0.1 ml of sterile phosphate-buffered saline, pH 7.2. C. albicans cells used for infection were obtained by inoculating 10 ml of sterile 1% phytone-peptone glucose broth with 100 RI of a stock blastospore suspension and then incubating the preparation for 22 h at 26°C in a shaking water bath. The resulting culture suspension was centrifuged for 10 min at 2,000 rpm at 4°C and resuspended in 1 to 2 ml of sterile phosphate-buffered saline. The number of blastospores in this suspension was counted in a hemacytometer. Thereafter, the yeast suspension was administered (0.1 ml per animal) via a short segment of butterfly tubing (1.5 in. or ca. 3.8 cm) affixed to a 1-ml tuberculin syringe.
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Treatment with ketoconazole or itraconazole (Janssen Pharmaceutica, Piscataway, N.J.) at dosages of 1.0, 2.5, 5.0, and 7.5 mg/kg, administered by daily gavage for either 3 or 5 days, was commenced 72 h after vaginal inoculation of the C. albicans strain. The presence of vaginal infection and therapeutic accomplishments were assessed by determining the numbers of candida present in the washes of the vagina carried out by lavage 3, 7, and 21 days after completion of the 3-and 5-day courses of therapy. Quantitation of the candida organisms present was made by serial dilution of the retrieved lavage fluid and plating on Sabouraud glucose agar. All plates were incubated at 30°C for 48 h for each series of dilutions; the plate, containing between 30 and 300 colonies, was used to calculate the log of the CFU per milliliter. For each dosage regimen, 10 oophorectomized rats were used. A control group of 10 untreated rats was similarly inoculated and lavaged, and quantitative cultures were performed. Successful treatment was equated with sterile vaginal lavage fluid. To verify results, 170 additional rats were studied under identical conditions except a second C. albicans vaginal isolate, BS1 (MICs of ketoconazole and itraconazole were each 0.098 p.g/ml), was used. The results of the two experiments involving 340 rats were pooled (Table  1) . Statistical analysis comparing the efficacy of ketoconazole and itraconazole was performed with the Student t test.
All 20 untreated rats became infected with a mean vaginal titer of log 5.6 ± 0.5 CFU/ml of vaginal fluid. At a dosage of 1.0 mg/kg, ketoconazole was ineffective in eradicating vaginal infection when administered for 3 or 5 days. In contrast, vaginal lavage on day 21 revealed that itraconazole successfully eradicated infection in 13 of 20 (65%) and 9 of 18 (50%) rats when administered for 5 and 3 days, respectively (P < 0.0001). Similarly, at a dosage of 2.5 mg/kg, ketoconazole was only marginally effective in sterilizing vaginal lavage fluid, even when administered for 5 days (7 of 20 rats). Once more, itraconazole at a dosage of 2.5 mg/kg was significantly superior in eradicating infection in that 72 and 65% of the rats cleared the infection after 5-and 3-day courses of therapy, respectively (P < 0.01). Only at dosages of 5.0 and 7.5 mg/kg did ketoconazole succeed in eradication of infection in more than 50% of the rats. However, at these higher dosage levels, itraconazole was still significantly superior, and sterile vaginal fluid was obtained in >90% of the rats (P < 0.01). No significant difference was observed when comparing itraconazole at dosages of 5.0 or 7.5 mg/kg, although vaginal clearing appeared to occur sooner with the higher dosage. Similarly, comparison of the efficacy of itraconazole at dosages of 5.0 and 7.5 mg/kg did not reveal any significant difference when 3-and 5-day courses of therapy were compared (P > 0.05).
Single-day therapy with itraconazole was investigated in a limited study at dosages of 7.5, 12.5, and 25.0 mg/kg administered by a single gavage. Ten rats were used for each dosage regimen. In addition, 10 rats were treated with single-day therapy in which 12.5 mg/kg was administered twice on the same day (total dose, 25.0 mg/kg). Single-day therapy with 25.0 mg/kg resulted in vaginal clearance of candida in the majority of rats (10 of 10 receiving a single dose and 8 of 10 receiving divided twice-daily doses) ( Table 1) .
Quantitative examination of vaginal titers of C. albicans in treated rats (data not shown) revealed a carry-over effect with itraconazole in that rats would frequently demonstrate a progressive decrease in vaginal titers of candida long after completion of therapy, resulting in the highest clearance rate by day 21. This was particularly evident with the 1-and 3-day courses of therapy. Furthermore, vaginal relapse, defined as sterile initial posttreatment vaginal fluid that subsequently became culture positive on repeat lavage performed on day 21, was only rarely seen with itraconazole (3 of 156 animals).
In summary, itraconazole in vivo was significantly more efficacious than ketoconazole in eradicating candida vaginal infection. On the basis of these observations, studies are required to confirm the efficacy of itraconazole in humans, particularly with regard to the use of itraconazole as singledose therapy. 
